Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nebicapone on Warfarin PK/PD in Healthy Volunteers
NCT02779348Phase 1Completed
- Sponsor
- BIAL
- Start
- Sep 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nebicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Mean Cmax of S-warfarin at 144 hours, Mean tmax of S-warfarin at 144 hours and 8 more. Started Sep 2006; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02779348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779348.